Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.

E, Rexhaj; S, Bär; R, Soria; Y, Ueki; JD, Häner; T, Otsuka; R, Kavaliauskaite; GC, Siontis; S, Stortecky; H, Shibutani; D, Spirk; T, Engstrøm; I, Lang; L, Morf; M, Ambühl; S, Windecker; S, Losdat; KC, Koskinas; L, Räber

doi:10.1016/j.atherosclerosis.2024.117504

Public

Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.

Shared by NobleBlocks on Mar 6, 2024 • 12:00 AM UTC

Authors:

Rexhaj E

Bär S

Soria R

Abstract

<h4>Background and aims</h4>The effects of protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on endothelial function as assessed by flow-mediated dilation (FMD) in patients with acute myocardial infarction (AMI) are unknown. Therefore, we aimed to investigate the effects of the PCSK9 inh...

Subject

Endothelial function

Coronary Atherosclerosis

Flow-mediated Dilation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!